

To expedite processing, please send the following information with prescription.

| Referral Form  | List of Tried and Failed Meds<br>(Including other Biologics) |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|
| Demographic Sheet                                      | Prescription Insurance Card<br>(Front & Back)                |  |  |  |  |  |  |  |
| Most Recent Clinical Notes                             |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Bio-Coordinator or Primary Point of Contact at Clinic: |  |  |  |  |  |  |  |  |
| Name:  |  |  |  |  |  |  |  |  |
| Email:   |  |  |  |  |  |  |  |  |

Direct Phone Line: \_\_\_\_\_

| Cell (optional, but preferred): - |  |
|-----------------------------------|--|
|                                   |  |

**Genefic Specialty Pharmacy** 2577 Mall Road, Suite B Florence, AL, 35630

> Phone: (833) 928-7660 Fax: (833) 928-7661 Website: GeneficRx.com

Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Genefic Specialty Pharmacy.

|  |  |  | Pres   | Prescriber:   |   |            |               |                            | NPI:       |                                |         |
|--|--|--|--|---|---|------------|---------------|----------------------------|------------|--------------------------------|---------|
| Gastrointestinal   |  |  | Supe   | ervising Physic   | cian:   | NPI:       |               |                            |            |                                |         |
| Enrollment Form  |  | Addr   | ess:   |   |   |            |               | Tax ID:                    |            |                                |         |
| I - Z  |  |  |  | Phon  | ie:   |            |               | Fax:                       |            |                                |         |
|  |  |  |  | Cont  | act:  |            |               |                            |            |                                |         |
| PATIENT INFORMATION  |  |  |  |   |   |            |               |                            |            |                                |         |
| Name:  |  |  |  |   | Trans F   |            | B:            |                            |            | SS#:                           |         |
| Street:  |  |  |  | City:   |   | State:     | /             | /<br>ZIP:                  |            | <del></del>                    |         |
| Phone:   |  | Alt. Phone:  |  |   |   |            |               |                            | Wt.:       | Ht.:                           |         |
| Filone.  |  | AIL FIIONE.  |  |   | English E   | · ·        | Other         | :                          | vvt        | n                              |         |
|  |  |  |  |   | RESCRIPTIC  |            |               |                            | _          |                                |         |
| -  | received a loading dose                      | e/starter kit? ⊔γ  | es Start Date  | :/  | /   |            |               |                            |            | tor's Office 🛛 Other:          |         |
| Drug   |  |  |  | T-1 45  |   |            | rections &    |                            |            |                                | Refills |
|  | 45 mg Tablets                                |  | <ul> <li>INITIAL: Take 45 mg PO once daily (Quantity: 28 with 1 refill) ***Intended for patients with Ulcerative Colitis***</li> <li>INITIAL: Take 45 mg PO once daily (Quantity: 28 with 2 refills) ***Intended for patients with Crohn's disease***</li> </ul> |   |   |            |               |                            |            | -                              |         |
| Rinvoq®  | 15 mg Tablets                                |  | INITIAL: 1 ake 45 mg PO once daily (Quantity: 28 with 2 refills) ***Intended for patients with Crohn's disease*** MAINTENANCE: Take 15 mg PO once daily (Quantity: 30)   |   |   |            |               |                            |            | -                              |         |
|  | 30 mg Tablets                                |  | MAINTENANCE: Take 15 mg PO once daily (Quantity: 30) MAINTENANCE: Take 30 mg PO once daily (Quantity: 30)  |   |   |            |               |                            |            |                                |         |
|  | 100 mg SmartJect®                            | Pen  |  |   |   |            |               | week 2 (Quantity           | : 3)       |                                |         |
| Simponi®   | 100 mg Pre-filled Sy                         |  |  |   | Inject 100 mg S   |            |               |                            |            |                                |         |
|  | □ 600 mg/10 mL Vial                          |  |  |   |   |            |               | antity: 1 with 2 re        |            |                                |         |
| 0  | □ 180 mg/1.2 mL Pre-<br>via On-Body Injector | filled cartridge   | thereafter (C  |   |   | SQ 4 weel  | ks after fina | l initial dose (wee        | ek 12), th | nen every 8 weeks              |         |
| Skyrizi®   | 360 mg/2.4 mL Pre-                           | filled cartridge   | · ·  | ,   | ,   | SQ 4 weel  | ks after fina | l initial dose (wee        | ek 12), th | nen every 8 weeks              |         |
|  | via On-Body Injector                         |  | thereafter (C  | uantity:  | 1)  |            |               |                            |            |                                |         |
| Stelara®   | □ 130 mg/26mL Vial                           | □ INITIAL INTRAVENOUS DOSAGE: A single intravenous infusion using weight-based dosing: Up to 55kg=260 mg (2 vials), >55kg to 85kg=390 mg (3 vials), >85kg=520 mg (4 vials) |  |   |   |            |               |                            |            |                                |         |
| Stelara  | Pre-filled Syringe                           |  |  | MAINTENANCE: Inject 90 mg SQ 8 weeks after initial dose, then every 8 weeks thereafter (1 syringe)  |   |            |               |                            |            |                                |         |
|  | Weight Required:<br>10 mg Tablets            |  |  | Taka 10   | mg PO twice d   | aily (Over |               | 1 rofill)                  |            |                                |         |
| Xeljanz®   | 5 mg Tablets                                 |  |  |   |   |            |               |                            |            |                                | -       |
| Aeijanz  |  |  |  |   | ANCE: Take 5 mg PO twice daily (Quantity: 60)<br>ANCE: Take 10 mg PO twice daily (Quantity: 60) |            |               |                            |            |                                |         |
|  | 22 mg Tablets                                |  | <b>—</b>   |   | mg PO once da   |            |               |                            |            |                                |         |
| Xeljanz® XR  |  |  |  |   | ANCE: Take 11 mg PO once daily (Quantity: 30)   |            |               |                            |            |                                |         |
|  | 22 mg Tablets                                |  |  |   | Take 22 mg P0   |            |               |                            |            |                                |         |
|  |  |  |  | : Take as directed per package instructions (Quantity: QS)  |   |            |               |                            |            |                                |         |
| Zeposia®   |  |  |  | red assessments are completed and the patient is cleared for therapy<br>NANCE: Take 0.92 mg by mouth once daily starting on day 8 and thereafter (Quantity: 30) |   |            |               |                            |            | -                              |         |
|  |  |  |  |   |   |            |               | ps://www.zeposia           |            |                                |         |
|  |  |  |  |   |   |            | <u></u>       | <u>55,77 TTTTL200 0010</u> | portanet   |                                |         |
| ***PLEASE F  |  |  |  |   |   |            |               | ANY CLINICAL               |            | S REGARDING THER               |         |
| PREVIOUS TH  |  | Tried & Failed   |  |   |   | Folerate   |               |                            |            | traindication:                 |         |
| <ul> <li>Methotrexate</li> <li>Pentasa</li> </ul>  |  |  | )  |   |   |            |               |                            |            |                                | -       |
| Cimzia   |  |  | )  |   |   |            |               |                            |            |                                | -       |
|  |  |  | )  |   |   |            |               |                            |            |                                | -       |
| □ <sub>Humira</sub>  |  |  | /  |   |   |            |               |                            |            |                                | -       |
|  | s disease of small intesti                   | ne. without compli   | cations  |   | D K50.1   | 0 Crohn's  | s disease o   | f large intestine, v       | vithout c  | complications                  |         |
|  | s disease of both intestin                   |  |  |   |   |            |               | nspecified, without        |            |                                |         |
| L K51.80 Other L   | Jlcerative Colitis, without                  |  |  |   |   |            |               | inspecified, witho         |            |                                |         |
| □ <sub>Other:</sub>  |  |  |  |   |   |            |               |                            |            |                                |         |
| Date of Diagnosi   |  | _  |  | llergies  |   |            |               |                            |            |                                |         |
| Active TB is ruled out: PYes No Date: / / Hep B ruled out/treated: Yes No Date: / / /  |  |  |  |   |   |            |               |                            |            |                                |         |
| Patient is steroi  |  |  |  |   |   |            |               |                            |            |                                |         |
|  |  |  |  | IN.II   | ECTION TRAIN  | ling       |               |                            |            |                                |         |
| INJECTION TRAINING   |  |  |  |   |   |            |               |                            |            |                                |         |
|  | · · · · · · · · · · · · · · · · · · ·        |  |  | PRES  | CRIBER SIGN/  | ATURE      |               | your prior outbari-        | ation do   | signated agont in dealing with |         |
| To Prescriber: By signing this form and utilizing our services, you are also authorizing Genefic Specialty Pharmacy to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.   |  |  |  |   |   |            |               |                            |            |                                |         |
| Prescriber: Date:  |  |  |  |   |   |            |               |                            |            |                                |         |
| CONFIDENTIALITY NOTICE   |  |  |  |   |   |            |               |                            |            |                                |         |
| IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this |  |  |  |   |   |            |               |                            |            |                                |         |
| document immediately.  |  |  |  |   |   |            |               |                            |            |                                |         |